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Downregulation and functional deactivation of
the transcriptional coactivator PGC-1a has
been implicated in heart failure pathogenesis.
We hypothesized that the estrogen-related
receptor a (ERRa), which recruits PGC-1a to
metabolic target genes in heart, exerts protec-
tive effects in the context of stressors known
to cause heart failure. ERRa/ mice subjected
to left ventricular (LV) pressure overload devel-
oped signatures of heart failure including cham-
ber dilatation and reduced LV fractional short-
ening. 31P-NMR studies revealed abnormal
phosphocreatine depletion in ERRa/ hearts
subjected to hemodynamic stress, indicative
of a defect in ATP reserve. Mitochondrial respi-
ration studies demonstrated reduced maximal
ATP synthesis rates in ERRa/ hearts. Cardiac
ERRa target genes involved in energy substrate
oxidation, ATP synthesis, and phosphate trans-
fer were downregulated in ERRa/ mice at
baseline or with pressure overload. These re-
sults demonstrate that the nuclear receptor
ERRa is required for the adaptive bioenergetic
response to hemodynamic stressors known to
cause heart failure.
INTRODUCTION
The adult heart undergoes distinct forms of hypertrophic
growth. Physiologic hypertrophy, during postnatal devel-
opment or with endurance training (‘‘runner’s heart’’), en-
hances functional capacity through coordinated increases
in cardiac mass and O2 consumption, thereby matchingmitochondrial respiratory capacity with energetic demand
(Strøm et al., 2005). Pathophysiologic stressors, such as
chronic pressure or volume overload, induce hypertrophic
growth accompanied by a dissociation of increased car-
diac mass and workload from available energy reserves
(Anversa et al., 1978; Kayar and Weiss, 1992). Pathologic
hypertrophy predisposes to cardiac dysfunction and fail-
ure through a remodeling process that is incompletely
understood. Whereas pathologic hypertrophy is an inde-
pendent risk factor for future heart failure and death (Vakili
et al., 2001), physiologic hypertrophy may be cardiopro-
tective. Characterization of distinct regulatory pathways
involved in adaptive versus maladaptive hypertrophic
remodeling may reveal novel therapeutic targets for heart
failure.
Discrete molecular signatures distinguish pathologic
from physiologic cardiac hypertrophic growth (Iemitsu
et al., 2001). One characteristic shift occurs in gene pro-
grams involved in cardiac fuel and energy metabolism.
Mitochondrial fatty acid oxidation (FAO) genes are down-
regulated in pathologic cardiac hypertrophy consistent
with a shift from FAO to glucose utilization for ATP syn-
thesis in the failing heart (Allard et al., 1994; Christe and
Rodgers, 1994; de las Fuentes et al., 2003; Strøm et al.,
2005). This fuel shift likely serves an early compensatory
role to maintain contractile function while minimizing O2
consumption costs. Over time, ATP synthetic capacity is
diminished in the pathologically hypertrophied heart.
Magnetic resonance spectroscopy has shown reduced
‘‘high-energy’’ phosphate stores in compensated pres-
sure overload-induced ventricular hypertrophy in animal
models and humans that progressively declines during the
transition to heart failure (see Ingwall and Weiss, 2004, for
review). Phosphocreatine (PCr), the major phosphate pool
and ATP buffer, is reduced in compensated hypertrophy
prior to any decline in contractile function, suggesting a
primary role in progression from compensated hypertro-
phy to failure (de Roos et al., 1992; Ingwall et al., 1985;Cell Metabolism 6, 25–37, July 2007 ª2007 Elsevier Inc. 25
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failure severity and is a strong predictor of cardiovascular
mortality (Neubauer et al., 1997; Neubauer, 2007). In addi-
tion, creatine kinase (CK)-mediated flux between PCr and
ATP is reduced in failing human hearts (Weiss et al., 2005).
Such observations support the notion that regardless of
primary etiology, functional deterioration of the hypertro-
phied heart has an energetic basis (Ashrafian et al., 2003;
Maloyan et al., 2005).
The regulatory events driving [PCr] depletion in the hy-
pertrophied heart have not been fully elucidated. PPARg
coactivator-1a (PGC-1a) is an inducible, cardiac-enriched
coactivator integrating upstream signals with transcription
factors regulating cellular energy metabolism, mitochon-
drial respiration, and replication/transcription of the mito-
chondrial genome (Finck and Kelly, 2006; Lin et al., 2005).
PGC-1a is upregulated in exercise-induced physiologic
cardiac hypertrophy ([Wende et al., 2005]; A.R. Wende
and D.P.K., unpublished data) but decreased in patho-
logic cardiac hypertrophy (Garnier et al., 2003; Lehman
and Kelly, 2002). PGC-1a null (PGC-1a/) mice exhibit
impaired cardiac contractile responses to inotropic stimuli
and to exhaustive exercise (Leone et al., 2005). An inde-
pendent line of PGC-1a/ mice develops age-dependent
cardiomyopathy with reduced baseline myocardial PCr
and ATP levels (Arany et al., 2005) and heart failure follow-
ing prolonged pressure overload (Arany et al., 2006). In a
cdk9 transgenic mouse model of heart failure, decreased
mitochondrial gene expression correlated with PGC-1a
protein and activity levels, and myocyte apoptosis was
rescued by PGC-1a overexpression in this model (Sano
et al., 2004). Thus, maximal PGC-1a activity may be
required to maintain cardiac energetic capacity in the
context of prolonged pathologic stress to prevent cardiac
remodeling that leads to heart failure.
Despite evidence that PGC-1a contributes to the adap-
tive response during cardiac hypertrophic growth, little is
known about relevant downstream pathways. PGC-1a
coactivates a cascade of transcription factors (Finck and
Kelly, 2006; Huss and Kelly, 2005). Recently, the estrogen-
related receptor a (ERRa) was identified as a PGC-1a
transcriptional partner (Huss et al., 2002; Schreiber et al.,
2003). Subsequent studies revealed the central role of
the ERRa/PGC-1a complex in regulating oxidative energy
metabolism. ERRa is dependent on PGC-1a to activate
transcription in oxidative tissues, such as heart and
slow-twitch skeletal muscle, targeting genes involved in
mitochondrial FAO and other mitochondrial pathways
(Huss et al., 2004; Wende et al., 2005). Likewise, inhibiting
ERRa function with siRNA knockdown or inverse agonists
impairs induction of mitochondrial gene expression and
respiration by PGC-1a (Mootha et al., 2004; Schreiber
et al., 2004). ERRa also upregulates expression of tran-
scription factors downstream of PGC-1a, including
PPARa and nuclear respiratory factor-2 (NRF-2) (Huss
et al., 2004; Mootha et al., 2004). The present study eval-
uates the functional and energetic response of ERRa null
mice (ERRa/) to cardiac pressure overload. Loss of
ERRa predisposes to stress-induced depletion of high-26 Cell Metabolism 6, 25–37, July 2007 ª2007 Elsevier Inc.energy phosphate reserves and pathologic cardiac re-
modeling, demonstrating the importance of the ERRa/
PGC-1a pathway in myocardial adaptation to pathophys-
iological stress.
RESULTS
ERRa and PGC-1a Are Downregulated
in Pathologic Hypertrophy
Expression of ERR isoforms and related pathways down-
stream of PGC-1a was assessed in response to pressure
overload to investigate their potential role in pathologic
hypertrophy. Transcript levels were measured in LV of
wild-type (WT) mice subjected to transverse aortic con-
striction (TAC) or to a sham procedure (Figure 1A). ERRa
transcript levels were decreased 33% in hypertrophied
hearts 7d post-TAC. In contrast, no changes were ob-
served for other transcription factors within the PGC-1a
cascade, including ERRg, PPARa, PPARb, NRF-2a, or
PGC-1a itself (Figure 1A and Table 2). Expression was then
examined in a chronic neonatal aortic banding (NAB)
model in which hypertrophic growth progresses over an
8wk period. While PPARa (19%) and PGC-1a (27%)
were coordinately downregulated with ERRa (17%) by
Figure 1. Expression of ERRa and Related Transcriptional
Regulators of Cardiac Metabolism in Response to Pressure
Overload
Real-time PCR analysis of transcript expression in WT hearts sub-
jected to (A) 7d TAC (sham, n = 9; TAC, n = 10) or (B) neonatal arotic
banding (NAB) (sham, NAB, n = 14) procedures. Data represent
mean arbitrary units (±SE) normalized to WT, sham values (= 1.0).
Asterisks (*) indicate significant difference (p < 0.05) between sham
and pressure overload groups.
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ERRa Regulates Cardiac EnergeticsFigure 2. ERRa/ Hearts Are Smaller
with Normal Function and Histology
(A) (Left) Body weight (g) of WT (n = 21) and
ERRa/ (n = 22) mice. (middle) Absolute LV
mass (mg) and (right) LV mass index, LV
mass/BW (WT, n = 14; ERRa/, n = 18).
Bars represent mean (±SE) and asterisks indi-
cate significant difference (p < .005) between
WT and ERRa/.
(B) Ventricular myocardium of WT andERRa/
hearts stained with H&E or Trichrome. Electron
microscopic analysis of sarcomeric and mito-
chondrial ultrastructure.
(C) Hemodynamic parameters in WT (n = 5) and
ERRa/ (n = 4) mice. Heart rate and rate of sys-
tolic pressure development (+dP/dt) measured
at baseline and with dobutamine administration
(ng/min).NAB; similar to the results with TAC, ERRg expression
was unaffected (Figure 1B). Thus, ERRa expression is
decreased early in pathologic cardiac hypertrophy with
later downregulation of PGC-1a and other cascade
components.
ERRa/ Hearts Exhibit a Growth Defect with
Preserved Contractile Function
ERRa/ mice exhibit modest baseline phenotypic abnor-
malities, including altered oxidative fatty acid catabolism
in white adipose and reduced intestinal lipid absorption
(Carrier et al., 2004; Luo et al., 2003). Recently, a defect
in cold-induced thermogenesis has been described in
ERRa/ mice and attributed to deficient mitochondrial
capacity in brown adipose (Villena et al., 2007). Initial char-
acterization demonstrated that ERRa/ hearts are
smaller with lower LV mass (15.5%) and normalized LV/
BW ratio (11%) than WT littermates (Figure 2A). Light mi-
croscopic and ultrastructural examination revealed normal
myofibrillar and mitochondrial architecture in ERRa/
hearts with no apparent change in mitochondrial number
or size (Figure 2B).
Echocardiographic analysis revealed no functional
differences between ERRa/ and WT mice (Table S1).To assess contractility, hemodynamics were measured
in vivo at baseline and following infusion of the b-adrener-
gic agonist, dobutamine. Heart rate, peak LV pressures,
and rates of pressure development and relaxation (±dP/
dt) were indistinguishable between WT and ERRa/
hearts at baseline and following dobutamine challenge
(Figure 2C and data not shown). Thus, ERRa deficiency re-
sults in a modest growth defect with normal contractile
function.
Pathologic Remodeling of ERRa/ Hearts
in Response to Pressure Overload
The increased workload imposed by chronic pressure
overload increases energetic demand. Given the hypoth-
esis that ERRa plays a prominent role in regulating cardiac
energy metabolism, we predicted that ERRa is essential
for myocardial adaptation during hypertrophic growth.
To test this hypothesis, adult WT and ERRa/ animals
were subjected to a 7d TAC protocol. Both groups ex-
hibited a significant increase in LV mass indexed to body
weight (Figure 3A) or tibia length (data not shown). Consis-
tent with the hypertrophic response, pressure gradients
achieved across the aortic constriction measured by
Doppler velocity indicated that a significant gradient wasCell Metabolism 6, 25–37, July 2007 ª2007 Elsevier Inc. 27
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ERRa Regulates Cardiac EnergeticsFigure 3. ERRa/ Hearts Undergo Pathologic Ventricular Remodeling in Response to Seven Day or Chronic Pressure Overload
(A) LV mass index in WT (sham, n = 9; TAC, n = 10) and ERRa/ (sham, n = 10; TAC, n = 12) mice. Data are reported as in Figure 2A.
(B) (left) M-mode echocardiographic (Echo) images from WT and ERRa/ mice subjected to sham or TAC. Echo-derived LV dimensions and func-
tional parameters: percent LV fractional shortening and relative wall thickness (RWT). Asterisks (*) indicate significant difference (p% 0.05) between
sham and TAC groups for a given genotype; daggers (y) denote significant difference (p% 0.05) between genotypes within a treatment group.
(C) H&E and Trichrome staining of ventricular myocardium from TAC animals. (inset) TUNEL staining (arrowheads denote positively stained cells).
(D) LV mass index in 8wk post-NAB WT (sham, n = 6; NAB, n = 5) and ERRa/ (sham, n = 4; NAB, n = 7) mice. Asterisks indicate significant mean
differences (p < .0005). Echo-derived parameters measured 8 week post-NAB: LV internal systolic chamber diameter, fractional shortening, and
RWT. Asterisks (*) indicate significant mean differences (p% 0.05) between sham versus NAB.achieved in all animals (Table S1 in the Supplemental Data
available with this article online). The response to TAC in
ERRa/ hearts was greater than that of WT animals such
that final mean LV weights were similar between the two
groups (Figure 3A) despite a slightly higher mean pressure
gradient achieved in the WT mice (Table S1). In contrast to
WT mice, which developed stable hypertrophy without LV
dilatation or systolic dysfunction, ERRa/ mice exhibited28 Cell Metabolism 6, 25–37, July 2007 ª2007 Elsevier Inc.echocardiographic characteristics of early heart failure
post-TAC. Specifically, mean LV fractional shortening (FS)
was significantly reduced in ERRa/ hearts subjected to
TAC (WT, 62.6 ± 2.2%; ERRa/, 48.0 ± 3.6%; p% 0.05;
Figure 3B; Table S1). LV systolic diameter increased sig-
nificantly in ERRa/ mice post-TAC compared to sham
controls or to WT mice post-TAC. In addition, relative wall
thickness (RWT) increased in WT TAC mice, a normal
Cell Metabolism
ERRa Regulates Cardiac Energeticsadaptive response to pressure overload; whereas RWT
was unchanged in the ERRa/ TAC hearts, indicating
wall thinning (Figure 3B; Table S1). Consistently, fibrosis
and apoptotic cell death were only observed in ERRa/
TAC hearts (Figure 3C).
Short-term TAC does not provide information about LV
remodeling in response to progressive chronic ventricular
pressure overload; therefore, mice were subjected to the
NAB protocol. Wt and ERRa/ hearts exhibited dramatic
hypertrophic growth (>50% increase) with NAB compared
to sham controls (Figure 3D). Equivalent pressure gradi-
ents developed in both groups (data not shown). Consis-
tent with the pathologic remodeling observed in response
to TAC, only ERRa/ hearts dilated and developed LV
systolic dysfunction, indicated by diminished %FS and
increased LV systolic chamber diameter (Figure 3D).
Reduced High-Energy Phosphate Reserve and ATP
Synthetic Capacity in ERRa/ Hearts
To investigate the basis for contractile failure in ERRa/
mice caused by pressure overload, we evaluated ener-
getic parameters inERRa/ hearts. Analysis of ultrastruc-
ture in ventricular samples of ERRa/ hearts post-NAB
revealed no overt mitochondrial pathology compared to
WT hearts (data not shown). 31P-NMR spectroscopy was
used to measure myocardial phosphocreatine (PCr) and
ATP levels in isolated perfused WT and ERRa/ hearts.
Baseline [PCr]/[ATP] ratios were equivalent in WT (1.6 ±
0.1) and ERRa/ (1.5 ± 0.1) hearts (Figure 4A). As ex-
pected, contractile parameters measured concurrently
with the spectroscopic analysis, were also normal in
ERRa/ hearts (Figure 4B).
The stress of TAC and NAB unveiled a contractile phe-
notype in ERRa/ mice. Thus, to determine whether the
functional response of ERRa/ hearts reflected a latent
energetic defect, myocardial [PCr] and [ATP] and contrac-
tile function were simultaneously measured in isolated WT
and ERRa/ hearts following increased work induced by
b-adrenergic infusion. Wt and ERRa/ hearts responded
to isoproterenol similarly with an appropriate increase in
heart rate, LV developed pressure (LVDP), and ± dP/dt
(Figure 4B). [ATP] was unchanged during b-agonist infu-
sion in both WT and ERRa/ hearts (Figure 4C). However,
[PCr] was depleted to a greater extent in ERRa/ hearts
compared to WT at 1 nM (WT, 91.8 ± 5.2%; ERRa/,
66.2 ± 5.7%; p % 0.01) and 5 mM (WT, 73.7 ± 6.3%;
ERRa/, 50.5 ± 6.5%; p % 0.03) isoproterenol
(Figure 4C).
Subsequently, hearts were subjected to 15 min of no-
flow ischemia followed by 40 min of aerobic reperfusion
(I/R). The ischemic period depletes PCr and ATP stores,
so rates of depletion and functional recovery can be
assessed. During the ischemic phase, despite WT and
ERRa/ hearts having equivalent initial [ATP], the rate of
[ATP] depletion in ERRa/ hearts was more rapid than
in controls (Figure 4D). During the 40 min reperfusion pe-
riod, when oxidative ATP production is re-initiated, [PCr]
recovery rate was slower during the early reflow period
(10 and 20 min) forERRa/compared to WT hearts, whichexhibited a commonly observed [PCr] overshoot (>100%
of pre-ischemic levels) at these time points, though by
the end of reperfusion (40 min) [PCr] had normalized be-
tween the two groups (Figure 4E). In contrast, [ATP] was
equivalent at the 10 and 20 min reflow time points, but
reduced in ERRa/ hearts compared to WT at the end
of reperfusion. Correlating with reduced [ATP], recovery
of contractile parameters, rate pressure product (RPP)
and LVDP, was impaired in ERRa/ hearts (Figure 4F).
Collectively, the reduced capacity for [PCr] and [ATP] re-
pletion in response to energetic stress is consistent with
defects in ATP synthesis inERRa/ hearts, and the result-
ing decrease in ventricular performance is a consequence
of depleted ATP pools.
To further assess ATP synthetic capacity of ERRa/
hearts, mitochondrial respiratory function and ATP syn-
thesis rates were assessed in endocardial strips prepared
from WT and ERRa/ mice. Measurement of O2 con-
sumption using palmitoylcarnitine (PC) or pyruvate (Fig-
ure 4G) as substrates revealed that basal (-ADP) and State
3 (+ADP, maximally stimulated) rates were not different
between the groups. In contrast, the ATP synthesis rate
normalized to O2 consumption (ATP/O) in ERRa
/ car-
diac strips was reduced with both PC (49.6%) and pyru-
vate (38.6%) compared to WT tissue (Figure 4H).
Pathologic Cardiac Remodeling in ERRa/ Mice
Correlates with Altered Expression of Genes
Involved in ATP Synthesis and High-Energy
Phosphate Transfer
To delineate ERRa target pathways involved in the bioen-
ergetic and functional abnormalities in ERRa/ hearts mi-
croarray analyses were performed to characterize gene
expression changes in these hearts. The number of meta-
bolic genes downregulated was relatively low, consistent
with the absence of functional baseline abnormalities in
the ERRa/ hearts. However, expression of genes in-
volved in multiple energy metabolic pathways was altered
in ERRa/ hearts including fatty acid uptake and oxida-
tion (fatty acyl-CoA synthase, CD36/fatty acid transporter,
acyl-CoA oxidase); TCA cycle (isocitrate dehydrogenase
2); ETC/Oxphos (NADH dehydrogenase 1b3, cytochrome
oxidase subunit VIIIb, ATP synthase 5e); and ATP phos-
phate transfer (mitochondrial creatine kinase 2) (Table 1).
Many of these genes were previously identified as candi-
date ERRa targets in gain-of-function studies performed
by our group and others (Huss et al., 2004; Mootha
et al., 2004; Schreiber et al., 2004). A second strategy, em-
ploying ERRa chromatin immunoprecipitation coupled to
promoter arrays (ChIP-chip) further informed our selection
of putative ERRa target genes for validation by real-time
PCR. These latter studies are described in detail in an
independent report (Dufour et al., 2007).
The complementary unbiased approaches identified
overlapping candidate energy metabolic pathways rele-
vant to the ERRa/ cardiac phenotype. Importantly,
ERRa target genes involved in ATP synthesis and high-en-
ergy phosphate transfer were identified. Expression of
these genes was evaluated using real-time PCR in allCell Metabolism 6, 25–37, July 2007 ª2007 Elsevier Inc. 29
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ERRa Regulates Cardiac EnergeticsFigure 4. Defects in Cardiac Energetics in ERRa/ Mice
(A) 31P-NMR baseline spectra, showing peaks for PCr, ATP phosphates (a, b, g) and free phosphate (Pi).
(B–E) (B) Hemodynamics and (C) PCr and ATP levels measured at baseline and after 1 nM and 5 nM isoproterenol (Iso) administration. Measurements
of PCr and ATP during (D) ischemia and (E) following reperfusion.
(F) Recovery of contractile function after reperfusion. RPP, rate pressure product; LVDP, left ventricular developed pressure; EDP, end-diastolic pres-
sure. Data represent mean percent measurements (±SE) relative to baseline values (set to 100%), and asterisks (*) indicate significant difference (p <
0.05) between WT and ERRa/ (n = 7).
(G) Mitochondrial respiration in WT or ERRa/ endocardial strips using palmitoylcarnitine (PC) or pyruvate as substrates. O2 was measured at basal
state, maximal (+ADP), and plus oligomycin (+oligo).
(H) ATP synthesis rates measured with PC (left) or pyruvate (right) as respiration substrates. Asterisks (*) indicate significant difference (p < 0.05)
between WT (n = 8) and ERRa/ (n = 10) hearts.four treatment groups (WT/sham, WT/TAC, ERRa//
sham, ERRa//TAC; Table 2). Genes involved in ATP
synthesis were dysregulated in a pattern consistent with
the metabolic and functional derangements observed
in ERRa/ hearts at baseline or in response to TAC. Spe-
cifically, ETC genes encoding subunits of Complex I
(Ndufs3), Complex II (SDHA), the electron transferring fla-30 Cell Metabolism 6, 25–37, July 2007 ª2007 Elsevier Inc.voprotein complex (Etfa and Etfd), and cytochrome c were
all significantly downregulated in ERRa//TAC but not
in the sham groups (Figure 5A, Table 2). This regulatory
pattern strongly suggested a link to the cardiac functional
phenotype; given that contractile dysfunction in the
ERRa/ hearts was unveiled with pressure overload,
when demands for ATP synthesis increase. In addition,
Cell Metabolism
ERRa Regulates Cardiac EnergeticsTable 1. Decreased Metabolic Genes in ERRa/ Hearts by Microarray Analysis
Accession Gene Symbol Gene Name
Lipid Metabolism
U15977 Acsl1 Fatty acyl-CoA synthetase, long chain
L23108 Cd36 CD36, fatty acid transporter
AF006688 Acox1 Acyl-CoA oxidase
Tricarboxylic Acid Cycle
U51167 Idh2 Isocitrate dehydrogenase 2
Electron Transport / Oxidative Metabolism
NM_025597 Ndufb3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 3
AV260484 Cox8b Cytochrome c oxidase subunit VIIIb
NM_025983 Atp5e ATP synthase H+ transporting, F1 complex, epsilon subunit
NM_198415 Ckmt2 Creatine kinase, mito 2 (sarcomeric)
Other Metabolic Processes
NM_024255 Hsdl2 Hydroxysteroid dehydrogenase like 2
XM_128781 Lycat Lysocardiolipin acyltransferase
Purine Nucleotide Metabolism
M74495 Adss Adenylosuccinate synthetase
X68193 Nme2 Nucleoside diphosphate kinase Btwo genes encoding enzymes functionally coupled to the
ATP synthase complex, mitochondrial creatine kinase 2
(mtCK2) and adenine nucleotide translocator 1 (ANT1),
were downregulated in ERRa/ hearts at baseline and
following TAC (Figure 5A, Tables 1 and 2). ANT1 and
mtCK2 coordinate phosphate transfer from nascent ATP
to creatine with the shuttling of regenerated ADP back
into the mitochondrial matrix (Saks et al., 2004). The re-
lated mtCK1 and CK-B genes were upregulated, suggest-
ing a switch in CK isoforms in ERRa/ hearts. Additional
genes involved in cardiac fuel utilization pathways, includ-
ing FAO (VLCAD) and glucose uptake (GLUT4), were also
downregulated in ERRa/ hearts (Figure 5A, Table 2).
The FAO gene MCAD was decreased only with the devel-
opment of dysfunction post-TAC. Collectively, these anal-
yses define potential ERRa targets and implicate causal
role for genes involved in ATP and PCr homeostasis in
the cardiac phenotype of ERRa/ mice.
Protein levels were assessed for a subset of the meta-
bolic targets and showed a similar pattern as the tran-
scripts, but with lower magnitude changes. Ndufs3 and
cyt c protein expression was lower in the ERRa/ hearts
(Figure 5C). Interestingly, cyt c protein was reduced in
sham and TAC ERRa/ hearts, whereas its transcript was
downregulated only in the TAC group (Figure 5C). Levels
of F1-ATPase subunit were decreased in ERRa
//TAC
hearts only; and VDAC1, involved in ATP translocation,
was reduced in sham and TAC ERRa/ hearts. Taken
together, the expression analyses suggest that reduced
expression of energy metabolic genes at baseline, as well
as in response to pressure overload, contributes to the
observed contractile failure in the ERRa/ hearts.A subset of ERRa target genes were downregulated
only following imposition of pressure overload (Figure 5A,
Table 2), suggesting that compensatory regulation pres-
ent under basal conditions, were deactivated during car-
diac hypertrophic growth. To explore this possibility, the
expression of several key transcription factors known to
share target genes with ERRa, including PGC-1, ERRg,
and NRF isoforms was assessed. Expression of ERRg,
PGC-1a, and Gabpa (NRF-2a) was increased in sham
ERRa/ hearts, an effect that was reversed following
TAC (Figure 5B, Table 2). These results suggest that com-
pensatory mechanisms maintain bioenergetic capacity in
unstressed ERRa/ hearts, but following pressure over-
load, a stimulus known to downregulate the PGC-1a reg-
ulatory circuit (Figure 1), this mechanism is deactivated.
DISCUSSION
The healthy adult heart has remarkable ATP synthetic
capacity and energetic reserve, matching oxidative ATP
synthesis with cardiac work. In response to chronic path-
ophysiologic loads, as occurs with hypertension, the hy-
pertrophied heart ultimately decompensates and fails.
Recent evidence implicates derangements in myocardial
bioenergetics in the transition from stable cardiac hyper-
trophy to heart failure (Allard et al., 1994; Christe and
Rodgers, 1994; de las Fuentes et al., 2003; Ingwall and
Weiss, 2004; Sack et al., 1997; Strøm et al., 2005; Ye
et al., 2001). The role of bioenergetic abnormalities as a
primary event in heart failure progression and the gene
regulatory pathways governing this metabolic ‘‘reprog-
ramming’’ have not been fully delineated. Herein, weCell Metabolism 6, 25–37, July 2007 ª2007 Elsevier Inc. 31
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ERRa Regulates Cardiac EnergeticsTable 2. Gene Expression Analysis by Real-time PCR in WT and ERRa/ Hearts at Baseline and Subjected to Seven
Day TAC
Common Name (Gene Symbol)
WT KO
Sham TAC Sham TAC
Lipid Metabolism
Medium-chain acyl-CoA dehydrogenase (Acadm) 1.0 (.08) 0.78 (.09) 0.82 (.1) 0.44 (.03)a,b
Very long-chain acyl-CoA dehydrogenase (Acadvl) 1.0 (.18) 0.86 (.06) 0.60 (.08)b 0.48 (.04)
Carnitine palmitoyltransferase 1b, muscle (Cpt1b) 1.0 (.14) 1.16 (.07) 1.15 (.07) 1.05 (.13)
Acyl-CoA oxidase (Acox1) 1.0 (.11) 0.81 (.09) 0.79 (.07) 0.69 (.06)
CD36/fatty acid transporter (Cd36) 1.0 (.12) 0.65 (.09)a 0.76 (.06) 0.57 (.07)
Carbohydrate Metabolism
GLUT1, glucose transporter 1, (Slc2a1) 1.0 (.06) 1.0 (.10) 1.35 (.12)b 1.35 (.16)b
GLUT4, glucose transporter 4, (Slc2a4) 1.0 (.19) 0.49 (.06)a 0.40 (.08)b 0.32 (.08)
Hexokinase 2 (Hk2) 1.0 (.07) 0.86 (.10) 1.02 (.14) 0.65 (.04)a
Electron Transport/Oxidative Metabolism
NADH dehydrogenase (ubiq.) 1b3 (Ndufb3) 1.0 (.07) 0.92 (.08) 1.03 (.10) 0.64 (.06)a,b
NADH dehydrogenase (ubiq.) 1b7 (Ndufb7) 1.0 (.11) 0.82 (.04) 0.83 (.06) 0.62 (.03)
NADH dehydrogenase (ubiq.) Fe-S protein 3 (Ndufs3) 1.0 (.09) 0.77 (.05) 1.05 (.06) 0.56 (.05)a
Succinate dehydrogenase subunit A (Sdha) 1.0 (.10) 0.97 (.10) 1.28 (.06) 0.80 (.06)a
Succinate dehydrogenase subunit B (Sdhb) 1.0 (.12) 0.82 (.08) 1.66 (.21)b 1.11 (.16)
Electron transferring flavoprotein, alpha (Etfa) 1.0 (.04) 0.80 (.08) 1.22 (.11) 0.68 (.07)a
Electron transferring flavoprotein, dehydrogenase (Etfdh) 1.0 (.11) 0.89 (.11) 1.74 (.34) 0.88 (.08)a
Cytochrome c (Cycs) 1.0 (.16) 1.19 (.13) 1.08 (.17) 0.64 (.09)b
Cytochrome c oxidase, subunit II (Cox2) 1.0 (.16) 1.03 (.1) 0.91 (.14) 0.91 (.16)
Cytochrome c oxidase, subunit IV isoform 1 (Cox4i1) 1.0 (.04) 0.95 (.03) 0.82 (.03)b 0.79 (.04)b
ATP synthase, H+ transporting F1 complex., beta (Atp5b) 1.0 (.12) 0.87 (.07) 0.95 (.1) 0.82 (.08)
Uncoupling protein 3 (Ucp3) 1.0 (.18) 0.50 (.1) 1.13 (.12) 1.50 (.42)b
Energy Transfer
Creatine kinase, mitochondrial 1, ubiquitous, (Ckmt1) 1.0 (.15) 0.96 (.12) 3.17 (.40)b 6.17 (1.65)a,b
Creatine kinase, mitochondrial 2, sarcomeric, (Ckmt2) 1.0 (.09) 0.68 (.08)a 0.78 (.06) 0.47 (.03)a
Creatine kinase, brain (Ckb) 1.0 (.08) 1.10 (.07) 1.55 (.17)b 1.59 (.09)b
Creatine kinase, muscle (Ckm) 1.0 (.05) 0.81 (.03) 0.93 (.09) 0.97 (.09)
Adenine nucleotide translocator 1 (Slc25a4) 1.0 (.13) 0.59 (.04)a 0.68 (.05)b 0.52 (.06)
Muscle Contraction and Hypertrophic Markers
Natriuretic peptide, type A (Nppa) 1.0 (.16) 4.57 (.88)a 3.02 (.47) 10.57 (1.94)a,b
Natriuretic peptide, type B (Nppb) 1.0 (.14) 2.75 (.59)a 1.13 (.23) 1.46 (.17)
b-myosin heavy chain (Myh7) 1.0 (.06) 4.13 (0.95)a 1.89 (.48) 2.87 (.34)
a-myosin heavy chain (Myh6) 1.0 (.09) 0.90 (.08) 0.98 (.09) 0.95 (.06)
ATPase, Ca2+-transporting, cardiac, Serca2a (Atp2a2) 1.0 (.15) 0.95 (.06) 0.87 (.13) 0.74 (.10)
Transcriptional Regulation
ERRg (Esrrg) 1.0 (.11) 1.08 (.09) 1.57 (.03)b 1.08 (.09)a
PGC-1a (Ppargc1a) 1.0 (.13) 1.15 (.09) 2.50 (.63)b 1.18 (.25)a
NRF-1, nuclear respiratory factor-1 (Nrf1) 1.0 (.08) 1.0 (.09) 1.66 (.13)b 1.72 (.13)b
Gabpa/NRF-2a, GA repeat binding protein, alpha (Gabpa) 1.0 (.11) 0.73 (.07) 1.52 (.13)b 0.91 (.08)a
mtTFA, transcription factor A, mitochondrial (Tfam) 1.0 (.09) 0.90 (.11) 0.78 (.06) 0.67 (.06)32 Cell Metabolism 6, 25–37, July 2007 ª2007 Elsevier Inc.
Cell Metabolism
ERRa Regulates Cardiac EnergeticsTable 2. Continued
Common Name (Gene Symbol)
WT KO
Sham TAC Sham TAC
PPARa (Ppara) 1.0 (.06) 1.0 (.07) 0.60 (.07)b 0.50 (.05)b
PPARb (Ppard) 1.0 (.16) 1.12 (.11) 1.20 (.08) 0.95 (.12)
a Sham versus TAC, p% 0.05.
b WT versus KO, p% 0.05, n = 7 for all groups.demonstrate that expression of the ERRa gene is downre-
gulated in the pathologically hypertrophied heart. More-
over, we found that deletion of the ERRa gene in mice
accelerates the bioenergetic and functional signatures of
heart failure in the context of pressure overload. These
results are important because ERRa, as a critical compo-
nent of the PGC-1a gene regulatory cascade, regulates
the transcription of genes involved in mitochondrial en-
ergy metabolism. These findings are consistent with inde-
pendent microarray datasets demonstrating ERRa down-
regulation in pathologic cardiac hypertrophy in mice and
heart failure in humans (Gene Expression Omnibus [GEO]database [Barrett et al., 2007]; GEO series accession:
GSE76; GSE1145).
Reduced high-energy phosphate stores ([PCr]), a meta-
bolic signature of pathologic cardiac hypertrophy and
heart failure, results from a mismatch in ATP supply and
demand (Ingwall and Weiss, 2004; Neubauer, 2007). Po-
tential mechanisms responsible for depletion of energy
stores include defects in ATP synthesis, alterations in mito-
chondrial ADP-ATP translocation, reduction in myocardial
substrate flux, and constraints on high-energy phosphate
transfer due to altered creatine kinase (CK) activity. ATP
flux through CK is reduced in humans with mild heart failureFigure 5. Decreased Expression of
Genes Involved in Cardiac Energy
Metabolism in ERRa/ Hearts
Real-time PCR expression analysis of genes
encoding (A) enzymes involved in energy
metabolism or (B) regulatory proteins was
assessed. Fatty acid and glucose utilization:
medium- and very long-chain acyl-CoA dehy-
drogenase (MCAD, VLCAD), glucose trans-
porter 4 (GLUT4); ETC/Oxphos targets: NADH
dehydrogenase (ubiquinone) Fe-S protein 3
(Ndufs3); succinate dehydrogenase subunit A
(SDHA); electron transferring flavoprotein de-
hydrogenase (Etfd); and cytochrome c (Cyt c);
Phosphate transfer: mitochondrial creatine
kinase 2 (mtCK2, sarcomeric), mtCK1 (ubiqui-
tous) and cytosolic brain-type CK (CK-B); (B)
Transcription factors: ERRg, PGC-1a and
PPARa. Data represent mean arbitrary units
(±SE) normalized to WT, sham values (= 1.0).
Asterisks (*) indicate significant difference
(p% 0.05) between sham and TAC groups for
a given genotype; daggers (y) denote signifi-
cant difference (p% 0.05) between genotypes
within a treatment group (all groups, n = 7).
(C) Immunoblot analysis of extracts from WT
or ERRa/ hearts subjected to sham or
TAC. Representative subunit proteins from
the ETC/Oxphos complexes were analyzed.
Voltage-dependent anion channel 1 (VDAC 1/
porin).Cell Metabolism 6, 25–37, July 2007 ª2007 Elsevier Inc. 33
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ERRa Regulates Cardiac Energetics(Weiss et al., 2005), resulting in loss of ATP buffering
capacity and increased direct reliance on mitochondrial
ATP synthesis which could limit the response to acute
and chronic increases in contractile demand. The impor-
tance of efficient, high capacity, mitochondrial ATP syn-
thesis is underscored by the cardiomyopathy phenotype
associated with genetic defects in these pathways (Pal-
mieri et al., 2005; Wallace, 2000).
Genetic defects in mitochondrial FAO, the key fuel
source for myocardial ATP synthesis, cause cardiomyop-
athy in humans (Bennett et al., 2000; Kelly and Strauss,
1994). Abnormalities in glucose metabolism are also asso-
ciated with cardiac dysfunction in animal models. Disrup-
tion of the insulin sensitive glucose transporter, GLUT4,
leads to cardiac hypertrophy and enhanced ischemia-
reperfusion injury (Tian and Abel, 2001; Weiss et al.,
2002). Our results indicate that whereas contractile func-
tion is normal at baseline, ERRa/ mouse hearts exhibit
decreased [PCr]/[ATP] and impaired PCr and ATP recov-
ery in response to adrenergic and ischemia-reperfusion
stress, respectively. Although not a direct measure of
ATP synthetic capacity, [PCR]/[ATP] is an index of cellular
energetics (Ingwall and Weiss, 2004; Neubauer, 2007).
Consistent with recent evidence that ERRa regulates
multiple pathways of cardiac mitochondrial energy me-
tabolism, we found that genes involved in FA and glucose
oxidation, TCA, ETC/Oxphos, and phosphate transfer are
perturbed in ERRa/ hearts at baseline and, in some
cases, to a greater degree following pressure overload.
These data support the conclusion that depletion of PCr
stores seen in ERRa/ hearts reflects underlying bioener-
getic defects related to reduced expression of genes
downstream of PGC-1a/ERRa. In further support of this
conclusion, respiration studies demonstrated that the ATP
synthesis/O2 consumption ratio is reduced in ERRa
/
hearts. We conclude that following pressure overload,
ERRa-deficient mice develop contractile dysfunction
due to abnormalities in both ATP synthesis and high-en-
ergy phosphate transfer as occurs in human forms of heart
failure.
The observed gene expression changes provide insight
into the basis for abnormal cardiac energetics in ERRa/
mice. Previous microarray studies in cardiac myocytes
overexpressing ERRa identified potential target genes
involved in energy substrate metabolism, including FA
uptake and oxidation, glucose metabolism, and ETC/
Oxphos (Huss et al., 2004). The same target genes were
decreased in ERRa/ hearts either at baseline (PPARa,
acyl-CoA synthase, CD36, acyl-CoA oxidase, VLCAD,
GLUT4, mtCK2, ANT1, and cytochrome oxidase subunits
IV and VIII) or following TAC (MCAD, hexokinse, Etfa,
Etfdh, Cyt c). Independent expression analyses support a
role for ERRa as a direct transcriptional regulator of genes
involved in cardiac fuel metabolism and energetics, a con-
clusion validated and expanded by the ChIP-chip studies.
The method and complete characterization of cardiac
ERRa gene targets by ChIP-chip was recently described
(Dufour et al., 2007). Collectively, our gene expression
results are consistent with the metabolic assessment of34 Cell Metabolism 6, 25–37, July 2007 ª2007 Elsevier Inc.ERRa/ hearts, indicating abnormalities in both ATP syn-
thetic capacity and PCr homeostasis. We found altered
expression of ERRa target genes involved in several path-
ways important for ATP synthesis including FAO, the TCA
cycle, ETC/Oxphos, and the ATP synthesis/translocation
complex. In addition, expression of the glucose trans-
porter, GLUT4, was downregulated in the ERRa/ hearts.
Whereas GLUT4 was not shown to be a direct ERRa target
in unbiased ChIP-chip studies (Dufour et al., 2007), the
ERRa/ hearts exhibit a downregulation of AMPKb sub-
units, Prkab1 and Prkab2, accompanied by reduced
AMPKa and ACC phosphorylation (Dufour et al., 2007).
The AMPK signaling pathway is an important regulator
of GLUT4 translocation and Slc2A4 transcription (Holmes
et al., 2005). Our studies also revealed evidence for abnor-
mal expression of genes involved in high-energy phos-
phate transfer, including mtCK and ANT1. ATP synthetic
capacity is also likely reduced due to inefficient synthesis,
possibly due to uncoupling. We observed no change in
UCP3 expression in ERRa/ hearts at baseline (Table
2), though UCP3 independent uncoupling has been re-
ported (Boudina et al., 2005). However, the expected
downregulation of UCP3 gene expression in response to
pressure overload (Taegtmeyer et al., 2002), did not occur
in the ERRa//TAC hearts, possibly resulting in a relative
increase in respiratory uncoupling and a reduction in ATP
synthetic capacity.
PGC-1a coactivates multiple nuclear receptor and non-
nuclear receptor transcription factors regulating distinct,
yet overlapping, gene targets involved in cardiac energy
metabolism (Huss and Kelly, 2005). This work identifies
ERRa, a specific PGC-1a partner, as important for the bio-
energetic and functional adaptation of the heart to hemo-
dynamic stress imposed by pressure overload. Since
ERRa regulates entire metabolic programs, the phenotype
of ERRa/ hearts cannot be ascribed to a single altered
target gene, except ERRa itself. In addition, the expression
pattern of PGC-1a and ERRg in ERRa/ hearts suggests
a ‘‘compensatory’’ response that is inactivated during
hypertrophy possibly accounting for pathologic cardiac
remodeling in ERRa/ mice. Indeed, as described in this
issue ofCellMetabolismby Alaynick et al., the cardiac phe-
notype of ERRgnull hearts supports the involvement of this
isoform in regulating cardiac energy metabolism (Alaynick
et al., 2007). The relevance of this putative compensatory
mechanism must be tested in experimental models that
prevent inactivation of the PGC-1a/ERRa pathway. Such
studies will help determine the therapeutic potential of tar-
geting the ERR/PGC-1a pathway for the treatment of heart
failure.
EXPERIMENTAL PROCEDURES
Animals
Adult (10–12 weeks) male WT or ERRa/ mice were studied. Wt and
ERRa/ mice are on the hybrid C57Bl6/svJ129 strain originally char-
acterized by the Gigue`re laboratory (Luo et al., 2003). The C57Bl6/
svJ129 line was maintained through successive generation inter-
crosses and baseline characterizations were performed on WT and
ERRa/ littermates from heterozygous (ERRa+/) matings. For TAC
Cell Metabolism
ERRa Regulates Cardiac Energeticsand NAB studies, WT or ERRa/ mice from heterozygous matings
(maintenance hybrid line) were mated to generate sufficient littermates
for treatments. Although experiments were performed on hybrid mice,
the pure strains (C57BL/6 or svJ129) respond similarly with mainte-
nance of ventricular function in the TAC pressure overload model
(unpublished data). Animal studies complied with NIH guidelines for
humane treatment of laboratory animals and were approved by the
Animal Studies Committee of Washington University.
Histology and Electron Microscopy
Midventricle slices were formalin-fixed, and paraffin-embedded sec-
tions stained with Masson’s trichrome or H&E for light microscopy.
For electron microscopy, LV papillary muscles were fixed in Karnov-
sky’s fixative, postfixed in 1% OsO4, and embedded in poly bed
812. Thin sections were stained with uranyl acetate/lead citrate.
Hemodynamic Studies
Hemodynamic studies were performed as previously described (Rock-
man et al., 1991). The right carotid artery of anesthetized mice (sodium
thiopental, 60 mg/kg) was cannulated with a 1.4-French high fidelity
micromonometer catheter (Millar Instruments), inserted into the left
atrium, advanced across the mitral valve, and secured in the LV.
Hemodynamic measurements were recorded at baseline and for
1 min increments following b1-adenergic receptor agonist (dobut-
amine) infusions (2, 4, 8, 16, 32 ng/gBW/min). Continuous aortic pres-
sures, LV systolic and diastolic pressures, and the derivative of
LV pressure (dP/dT) were collected and digitized with BioBench data
acquisition software (National Instruments).
Transverse Aortic Constriction and Neonatal
Aortic Banding Protocols
Transverse aortic constriction (TAC) is an established procedure for
producing LV hypertrophy (Rockman et al., 1991; Sack et al., 1997).
Wt or ERRa/ mice were anesthetized (ketamine [87 mg/kg]/xylazine
[13 mg/kg]). Following aortic dissection through intercostal muscles,
7.0 silk suture was tied around the transverse aorta and a blunt 27 g
needle, which was removed to introduce a tight constriction. For neo-
natal aortic banding (NAB), 18- to 20-day-old mice, weighing 12–15 g,
received ascending aortic constrictions as described above. Seven
days (TAC) or 8 weeks (NAB) postsurgery, noninvasive transthoracic
echocardiograms were performed (9:00-11:00 am). Hearts were ex-
cised from mice euthanized between 1:00-3:00 pm by CO2 inhalation,
and LV was dissected for analyses.
Heart Langendorff Perfusion and 31P NMR Spectroscopy
Spectroscopic analysis of hearts from untreated WT or ERRa/ mice
was performed as described (Cross et al., 2002; Imahashi et al., 2004).
Hearts were excised from anesthetized mice (sodium pentobarbital
[80 mg/kg]), cannulated and perfused in Langendorff mode at a con-
stant pressure of 90cm of H2O with phosphate-free Krebs-Heinseleit
buffer (37C, [pH 7.4]) containing (mmol/l): 120 NaCl, 11 glucose,
25 NaHCO3, 1.75 CaCl2, 5.9 KCl, and 1.2 MgSO4. Contractile function
was monitored with a latex balloon inserted into the LV and connected
to a pressure transducer (Argon/Maxxim Medical) and data were ac-
quired with PowerLab system (AD Instruments). Intracellular pH (pHi),
PCr, ATP and Pi, were continuously monitored by acquiring 5 min
31P
NMR spectra using a Varian Inova 500 MHz NMR spectrometer with
an 11.7 Tesla superconducting magnet at the 31P resonance frequency
of 202.47 MHz. The pHi was determined from chemical shift difference
between PCr and intracellular Pi resonances. Perfused hearts were sta-
bilized for 15 min while the magnet was shimmed and control NMR
spectra were acquired. Isoproterenol (1nM and 5nM) was infused for
5 min periods during which contractile and NMR measurements were
collected. After isoproterenol treatment, hearts were made globally
ischemic for 15 min followed by 40 min reperfusion. Recovery of post-
ischemic energetics and contractile function, expressed as percentage
of pre-ischemic function, was assessed.Mitochondrial Respiration Studies
Mitochondrial respiration rates were measured in saponin-permeabi-
lized endocardial strips from WT (n = 8) and ERRa/ (n = 9) mice as
described (Saks et al., 1998). Inner endocardial layer strips were dis-
sected from mixed endocardium/subendocardium slices initially ex-
cised from the LV. Endocardial fibers were separated along the long
bundle axis, and transferred to buffer with 50 mg/ml saponin for perme-
abilization. Respiration assays were performed in a sealed, water-jack-
eted (25C) chamber in respiration buffer containing 0.2 mM palmitoyl-
carnitine or 10 mM pyruvate (both with 5 mM malate) substrates as
described (Saks et al., 1998). Dissolved O2 was measured with a
FOXY-AL300 fiber optic probe coupled to a USB-LS-450 LED excita-
tion light source and USB2000 Spectophotometer (Ocean Optics) to
assess basal (-ADP, non-ATP generating), State 3 maximal (+ADP);
and uncoupled (+oligomycin, an ATP synthase inhibitor) respiration
rates. Rates were calculated from O2 consumption trace slopes (OOI
Sensors software) and expressed as nmol O2/min/mg tissue dry WT.
For ATP measurements, 10 ml aliquots were removed from State 3 re-
spiring strips in 10 s intervals, the chamber resealed, and O2 consump-
tion measured. Sample ATP content was analyzed by quantifying light
emission from recombinant luciferase enzyme and Enlighten luciferin
substrate (Promega). ATP concentrations were interpolated from a
standard curve.
DNA Microarray
Total mouse ventricle RNA was reverse transcribed (Superscript II,
Invitrogen Corp.) with T7 promoter-polyA primer (T7T24), followed by
second strand synthesis, and generation of biotin-labeled cRNA as
described (Huss et al., 2004). The Alvin Siteman Cancer Center’s Multi-
plexed Gene Analysis Core at Washington University School of Medi-
cine performed hybridization to Affymetrix mouse U74A chip. Affyme-
trix MAS 5.0 software was used for initial analysis and background
normalization, and subsequent data analysis was performed in Excel.
Probe sets called ‘‘absent’’ by MAS 5.0 in both WT and ERRa/ heart
samples were excluded. Signal intensities were normalized to average
intensity for all probe sets and ratios were calculated as ERRa/: WT.
Two independent trials using pooled RNA from 3 WT or ERRa/
hearts were performed. Signal intensity ratios % 0.5 in both trials
were considered as potentially downregulated targets in ERRa/
hearts. Data have been submitted to the NCBI database (GEO series
accession: GSE8106).
Quantitative Real-Time PCR and Immunoblot Analyses
Real-time PCR was performed to quantify relative cardiac transcript
levels in the various treatment groups. Applied Biosystems reagents
were used for reverse transcription (MultiScribe MuLV reverse tran-
scriptase) of RNA and real-time PCR reactions (SYBR green PCR or
TaqMan Universal PCR Master mixes) containing 0.4 mM gene specific
primers or primers plus 0.1 mM Taqman probes (50FAM and 30TAMRA
modified). Primer and probe sequences are provided in Table S2. PCR
reactions were analyzed in triplicate on the Applied Biosystems Prism
7500. Transcript levels were normalized to 36B4 ribosomal RNA.
For immunoblot analysis 40 mg of total protein extracted from the
heart apex was resolved on 9% SDS-PAGE and transferred to Protean
II nitrocellulose (Schleicher & Schuell). Overnight incubations (4C)
were performed with the primary antibodies: F1-ATPase (R-20, Santa
Cruz Biotechnology), mtCK2 (R-15, Santa Cruz Biotechnology), cyt c
(7H8.2C12) mAb (BD PharMingen), Ndufs3 complex I subunit (20C11)
mAb (Invitrogen), VDAC (N-18, Santa Cruz Biotechnology). Secondary
HRP-conjugated antibodies were detected by enhanced chemilumi-
nescence (Amersham Biosciences). The baseline protein analysis
was presented in Dufour et al. (Dufour et al., 2007), and is included
here for interpretation.
Statistical Analysis
All data are presented as mean ± standard error of the mean (SE).
Differences between mean values for cardiac weights (TAC and NAB
trials), real-time PCR, and echocardiographic analysis wereCell Metabolism 6, 25–37, July 2007 ª2007 Elsevier Inc. 35
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ERRa Regulates Cardiac Energeticsdetermined by a two-way ANOVA followed by Bonferroni post hoc
analysis with correction for multiple comparisons. For 31P-NMR spec-
troscopic studies significant difference was determined by unpaired
Student’s t test. A p value of % 0.05 was considered significantly
different.
Supplemental Data
Supplemental Data include two tables and can be found with this
article online at http://www.cellmetabolism.org/cgi/content/full/6/1/
25/DC1/.
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